Windtree Therapeutics (WINT) Competitors $0.06 0.00 (-1.63%) As of 02:38 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock WINT vs. PCSA, SNPX, ADXN, BFRI, CELZ, MTNB, AEON, CSCI, TSBX, and EVOKShould you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include Heatwurx (PCSA), Synaptogenix (SNPX), Addex Therapeutics (ADXN), Biofrontera (BFRI), Creative Medical Technology (CELZ), Matinas Biopharma (MTNB), AEON Biopharma (AEON), COSCIENS Biopharma (CSCI), Turnstone Biologics (TSBX), and Evoke Pharma (EVOK). These companies are all part of the "pharmaceutical products" industry. Windtree Therapeutics vs. Its Competitors Heatwurx Synaptogenix Addex Therapeutics Biofrontera Creative Medical Technology Matinas Biopharma AEON Biopharma COSCIENS Biopharma Turnstone Biologics Evoke Pharma Heatwurx (NASDAQ:PCSA) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk. Does the media refer more to PCSA or WINT? In the previous week, Heatwurx and Heatwurx both had 2 articles in the media. Heatwurx's average media sentiment score of 1.45 beat Windtree Therapeutics' score of 0.99 indicating that Heatwurx is being referred to more favorably in the media. Company Overall Sentiment Heatwurx Positive Windtree Therapeutics Positive Which has stronger earnings & valuation, PCSA or WINT? Heatwurx is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHeatwurxN/AN/A-$11.85M-$2.32-0.08Windtree TherapeuticsN/AN/A-$1.79M-$823.470.00 Which has more volatility & risk, PCSA or WINT? Heatwurx has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Do insiders & institutionals believe in PCSA or WINT? 91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are owned by institutional investors. 2.4% of Heatwurx shares are owned by insiders. Comparatively, 0.2% of Windtree Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is PCSA or WINT more profitable? Windtree Therapeutics' return on equity of -207.34% beat Heatwurx's return on equity.Company Net Margins Return on Equity Return on Assets HeatwurxN/A -342.36% -243.48% Windtree Therapeutics N/A -207.34%-50.19% Do analysts prefer PCSA or WINT? Heatwurx currently has a consensus target price of $1.00, indicating a potential upside of 415.46%. Windtree Therapeutics has a consensus target price of $350.00, indicating a potential upside of 581,295.35%. Given Windtree Therapeutics' higher possible upside, analysts plainly believe Windtree Therapeutics is more favorable than Heatwurx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Windtree Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryHeatwurx beats Windtree Therapeutics on 7 of the 12 factors compared between the two stocks. Get Windtree Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WINT vs. The Competition Export to ExcelMetricWindtree TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.77M$3.11B$5.75B$10.27BDividend YieldN/A2.32%5.73%4.60%P/E Ratio0.0021.4175.1826.37Price / SalesN/A240.50457.0688.69Price / CashN/A44.4425.8129.91Price / Book0.069.6113.256.28Net Income-$1.79M-$53.20M$3.29B$270.67M7 Day PerformanceN/A0.18%0.72%2.79%1 Month PerformanceN/A4.02%4.58%6.01%1 Year PerformanceN/A9.21%73.44%26.05% Windtree Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WINTWindtree Therapeutics2.0077 of 5 stars$0.06-1.6%$350.00+581,295.3%-100.0%$1.77MN/A0.0030Short Interest ↓Gap UpPCSAHeatwurx3.6918 of 5 stars$0.18+6.2%$1.00+447.9%-85.9%$8.65MN/A-0.0820Short Interest ↓SNPXSynaptogenixN/A$6.19+6.9%N/A+96.5%$8.60MN/A-0.614ADXNAddex Therapeutics3.1786 of 5 stars$7.90-2.3%$30.00+279.7%+11.0%$8.57M$460K-23.2430Positive NewsGap DownBFRIBiofrontera2.1758 of 5 stars$0.81-4.1%$2.75+239.5%-34.8%$8.56M$37.32M-0.3670Positive NewsShort Interest ↑Gap DownCELZCreative Medical Technology1.7808 of 5 stars$3.30-0.3%N/A+7.7%$8.54M$10K-1.045Gap DownMTNBMatinas Biopharma0.0808 of 5 stars$1.67-2.9%N/AN/A$8.50MN/A-0.3430Negative NewsShort Interest ↑Gap DownAEONAEON Biopharma3.1414 of 5 stars$0.73-5.0%$360.00+49,555.2%-98.5%$8.44MN/A4.035Short Interest ↓CSCICOSCIENS BiopharmaN/A$2.61-15.3%N/A-37.3%$8.29M$9.44M-0.4320Positive NewsGap DownHigh Trading VolumeTSBXTurnstone BiologicsN/A$0.36flat$0.45+26.8%N/A$8.22M$19.31M-0.1782EVOKEvoke Pharma0.1356 of 5 stars$5.20-0.2%N/A+20.0%$8.12M$10.25M-2.034Short Interest ↑Gap Down Related Companies and Tools Related Companies PCSA Competitors SNPX Competitors ADXN Competitors BFRI Competitors CELZ Competitors MTNB Competitors AEON Competitors CSCI Competitors TSBX Competitors EVOK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:WINT) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Windtree Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
